Related Experiment Video
Updated: Jul 21, 2025

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
Eculizumab for a catastrophic relapse in NMOSD: case report
David Gorriz1, Francisco Carlos Pérez-Miralles2, Carlos Quintanilla-Bordás2
1Neuroinmunology Unit, Neurology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain. gorriz_dav@gva.es.
This case report highlights a patient with severe Neuromyelitis Optica Spectrum Disorder (NMOSD) who responded positively to eculizumab after conventional treatments failed. The study also discusses the role of soluble neurofilament light chain (sNfL) in NMOSD management.
Area of Science:
- Neuroimmunology
- Central Nervous System Inflammatory Disorders
Background:
- Neuromyelitis Optica Spectrum Disorder (NMOSD) involves immune-mediated demyelination and axonal damage in the CNS, primarily affecting the spinal cord and optic nerves.
- Seropositive NMOSD, particularly aggressive forms, presents significant treatment challenges.
More Related Videos
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
09:41Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
Published on: January 20, 2023
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...